This article is more than 5 years old. Information may no longer be current.
SGLT-2 Inhibitors – An Emerging Class of Anti-hyperglycemic Agents
Click Here to Manage Email Alerts
Sponsorship Statement:
This continuing education activity is sponsored by 
Educational Partner: 
Support Statement:
This activity is supported by an educational grant from:
Target Audience: The intended audience for this activity is primary care physicians, internists, endocrinologists, cardiologists and other healthcare professionals involved in the treatment of obese patients at risk for co-morbid conditions.
Learning Objectives: At the conclusion of this activity participants should be able:
- Describe the classes of anti-hyperglycemic medications and their impact on weight
- Explain the mechanism of action of the SGLT-2 inhibitors
Course Chair:
Lawrence Blonde, MD, FACP, FACE
Director
Ochsner Diabetes Clinical Research Unit
Department of Endocrinology, Diabetes and Metabolic Diseases
Ochsner Medical Center
New Orleans, Louisiana
External Reviewer:
Ronald A. Codario, MD, FACP (Employee of Vindico Medical Education)
Accreditation:
Scripps Health is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
Credit Designation
Scripps Health designates this live activity for a maximum number of 0.25 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This enduring material is approved for 1 year from the date of original release July 2011 to July 2012.
How To Participate in this Activity and Obtain CME Credit:
To participate in this CME activity, you must read the objectives, answer the Pretest questions, watch and listen to the presentations, complete the Posttest, and complete the evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 2 out of 3 of the Posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the Posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)TM certificate.
Disclosures:
In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all CME providers are required to disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of CME content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the last 12 months with a commercial interest whose products or services are discussed in the CME activity content over which the individual has control. Relationship information appears on this page and the next page.
The authors disclose that they do have significant financial interests in any products or class of products discussed directly or indirectly in this activity, including research support.
Planning Committee and Faculty members report the following relationship(s):
Lawrence Blonde, MD, FACP, FACE
Consultant: Amylin Pharmaceuticals, Inc., AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Daiichi Sankyo, GlaxoSmithKline, Halozyme, Johnson & Johnson, Mannkind Corporation, Merck & Co., Inc., Novo Nordisk, Orexigen Therapeutics, Roche, Sanofi-Aventis, Santarus, VeroScience
Grant/Research Support to Institution: Boehringer Ingelheim Pharmaceuticals, Inc., Eli Lilly and Company, Johnson & Johnson, Novo Nordisk, Roche, Sanofi-Aventis
Speaker: AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Bristol-Myers Squibb, Daiichi Sankyo, Merck & Co., Novo Nordisk, Santarus, Vero Science
Spouse Financial Relationships: Dr. Blonde’s late spouse’s estate contains shares of Amylin Pharmaceuticals and Pfizer, Inc.
External Reviewer reports the following relationship(s):
Ronald A. Codario, MD, FACP
No relevant financial relationships to disclose.
Scripps Health and Vindico Medical Education staff report the following relationship(s):
No relevant financial relationships to disclose
Signed Disclosure(s) are on file at Scripps Conference Services & CME and Vindico Medical Education, Office of Medical Affairs and Compliance.
Unlabeled and Investigational Usage:
The audience is advised that this continuing medical education activity may contain references to unlabeled uses of FDA-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non-FDA approved or investigational use of products/devices.
Copyright Statement:
Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2011 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.